Panel Discussion | MCS for High-Risk PCI

Monday, March 9, 2026

11:48 AM - 12:10 PM EST

Location: CRT Center Stage

Moderator(s)

John Daniel Puskas, MD PhD(hc)

Professor of Cardiothoracic Surgery
Emory University
Atlanta, Georgia, United States

Disclosure(s): Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing); Scanlan Inc: Royalties on sale of coronary surgery instruments designed by Puskas (Ongoing)
John P. Reilly, MD

Chief of Cardiology
Stony Brook Southampton Hospital
Stony Brook, New York, United States

Disclosure(s): No financial relationships to disclose
Robert W. Yeh, MD, MSc

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure information not submitted.

Panel Discussant(s)

Arnav Kumar, MD, MSCR

Interventional Cardiologist Structural Heart Valve Specialist Assistant Professor of Medicine
University of Houston, HCA Medical Center
Houston, Texas, United States

Disclosure(s): No financial relationships to disclose
Fayaz Shawl, MD, FACC, FACP, FSCAI

Director, Interventional Cardiology
Adventist HeathCare WhiteOak Medical Center
Silver Spring , Maryland, United States

Disclosure(s): No financial relationships to disclose
Hiroo Takayama, MD, PhD

Chief, Adult Cardiac Surgery
Columbia University

Disclosure(s): Artivion: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

John Daniel Puskas, MD PhD(hc): Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Johnson and Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing); Scanlan Inc: Royalties on sale of coronary surgery instruments designed by Puskas (Ongoing)

John P. Reilly, MD: No financial relationships to disclose

Arnav Kumar, MD, MSCR: No financial relationships to disclose

Fayaz Shawl, MD, FACC, FACP, FSCAI: No financial relationships to disclose

Gregg W. Stone, MD, FACC, MSCAI: Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)

Hiroo Takayama, MD, PhD: Artivion: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing)